ArticleCommunications biology2021
Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis.
Open access · goldAbstract read
In one paragraph
Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 53 citations in OpenAlex.
- An Overview of the Factors Related toVaccines · 2026Review
- Leishmaniasis.Nature reviews. Disease primers · 2025Review
- Intracellular Parasitic Infections Caused byVaccines · 2025Review
- Evaluation ofMicrobiology spectrum · 2025Article
- LmCenNPJ vaccines · 2025Article
- Understanding Sex-biases in Kinetoplastid Infections: Leishmaniasis and Trypanosomiasis.Expert reviews in molecular medicine · 2025Review
- Downregulation of IRF7-mediated type-I interferon response by LmCenNPJ vaccines · 2024Article
- Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis.Nature medicine · 2024Observational
- CYP5122A1 encodes an essential sterol C4-methyl oxidase in Leishmania donovani and determines the antileishmanial activity of antifungal azoles.Nature communications · 2024Article
- An update on recombinant vaccines against leishmaniasis.The Indian journal of medical research · 2024Review
- Manufacturing and preclinical toxicity of GLP grade gene deleted attenuated Leishmania donovani parasite vaccine.Scientific reports · 2024Article
- Evidence for gene essentiality in Leishmania using CRISPR.PloS one · 2024Article
- Production of leishmanin skin test antigen from Leishmania donovani for future reintroduction in the field.Nature communications · 2023Article
- Article
- Article
- In search of a vaccine for leishmaniasis.Nature · 2023Article
- Next-Generation Leishmanization: Revisiting Molecular Targets for Selecting Genetically Engineered Live-AttenuatedMicroorganisms · 2023Review
- Immunogenicity and protective efficacy of tuzin protein as a vaccine candidate inFrontiers in immunology · 2023Article
- Centrin-deficient Leishmania mexicana confers protection against Old World visceral leishmaniasis.NPJ vaccines · 2022Article
- Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future.The Korean journal of parasitology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 8 institutions in 4 countries.
Subir KarmakarDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA.
Nevien IsmailDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA.
Fabiano OliveiraVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA.ORCID 0000-0002-7924-8038
James OristianVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA.
Wen Wei ZhangDepartment of Microbiology and Immunology, McGill University, Montreal, QC, Canada.ORCID 0000-0003-1996-876X
Swarnendu KavirajGennova Biopharmaceuticals, Hinjawadi Phase II, Pune, Maharashtra, India.
Kamaleshwar P SinghGennova Biopharmaceuticals, Hinjawadi Phase II, Pune, Maharashtra, India.
Abhishek MondalRajendra Memorial Research Institute of Medical Sciences, Patna, India.
Sushmita DasRajendra Memorial Research Institute of Medical Sciences, Patna, India.
Krishna PandeyRajendra Memorial Research Institute of Medical Sciences, Patna, India.
Parna BhattacharyaDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA.
Greta VolpedoDepartment of Pathology and Microbiology, Ohio State University, Columbus, OH, USA.
Sreenivas GannavaramDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA.ORCID 0000-0002-6557-8220
Monika SatoskarDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA.
Sanika SatoskarDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA.
Rajiv M SastryDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA.
Timur OljuskinDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA.ORCID 0000-0001-5494-2237
Telly SepahpourDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA.
Claudio MenesesVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA.
Shinjiro HamanoDepartment of Parasitology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Pradeep DasRajendra Memorial Research Institute of Medical Sciences, Patna, India.
Greg MatlashewskiDepartment of Microbiology and Immunology, McGill University, Montreal, QC, Canada. greg.matlashewski@mcgill.ca.ORCID 0000-0002-8971-5525
Sanjay SinghGennova Biopharmaceuticals, Hinjawadi Phase II, Pune, Maharashtra, India. Sanjay.Singh@gennova.co.in.
Shaden KamhawiVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA. skamhawi@niaid.nih.gov.ORCID 0000-0003-4304-636X
Ranadhir DeyDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA. Ranadhir.Dey@fda.hhs.gov.ORCID 0000-0003-0069-7867
Jesus G ValenzuelaVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA. jvalenzuela@niaid.nih.gov.ORCID 0000-0002-5589-9450
Abhay SatoskarDepartment of Pathology and Microbiology, Ohio State University, Columbus, OH, USA. Abhay.Satoskar@osumc.edu.
Hira L NakhasiDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA. Hira.Nakhasi@fda.hhs.gov.ORCID 0000-0003-4941-1620
Vector (United States) · USRajendra Memorial Research Institute of Medical Sciences · INCenter for Biologics Evaluation and Research · USThe Ohio State University · USBiotech Park · INMcGill Genome Centre · CAMcGill University · CANagasaki University · JP
Funding
Molecular approaches to understand vector-host and vector-pathogen interactionsZIAAI000932 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI VALENZUELA, JESUS · 2009 to 2025
$23.1MCIHR
Abstract
Visceral Leishmaniasis (VL), a potentially fatal disease is caused by Leishmania donovani parasites with no vaccine available. Here we produced a dermotropic live attenuated centrin gene deleted Leishmania major (LmCen
Indexed as
Gene DeletionGenes, ProtozoanLeishmania donovaniLeishmaniasis VaccinesLeishmaniasis, VisceralProtozoan ProteinsVaccines, AttenuatedLeishmaniasis VaccinesProtozoan ProteinsVaccines, Attenuated
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.